Healthy Stool Volunteer Donors for Fecal Microbiota Transplantation Trials
NCT ID: NCT06478823
Last Updated: 2024-07-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
400 participants
INTERVENTIONAL
2024-07-08
2030-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Profiling Fecal Samples for Selection of Donors of Feces
NCT04078581
Fecal Transplantation to Eradicate Colonizing Emergent Superbugs
NCT05035342
Search Cytomegalovirus in Healthy Volunteers Stools Samples Selected as Potential Donor for Fecal Microbiota Transplant
NCT02694484
Fecal Microbiota Transplant (FMT) for Relapsing C. Difficile Infection in Adults and Children Using a Frozen Inoculum
NCT01704937
Placebo Controlled Study of Fecal Microbiota Transplant (FMT) for a First or Second Episode of C. Difficile Infection in Adults Using a Frozen Encapsulated Inoculum
NCT02343328
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Healthy voluntary donors of stools for the preparation of TMF (Healthy Volunteer Donors, -TMF) for trials to evaluate its effectiveness in various pathologies will be selected, included and followed in a common protocol (ANSM agreement obtained) in order to facilitate this entire process and pool resources. This will allow us to describe the clinical characteristics and lifestyle habits of Healthy Volunteer Donors associated with the validity of stool donations.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy volunteers for stool donation
Stools donation
Healthy volunteer donors included in the selection process to donate stool for the preparation of a TMF as part of research projects.
Donors will be followed from their selection until 6 months after their last valid stool donation.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Stools donation
Healthy volunteer donors included in the selection process to donate stool for the preparation of a TMF as part of research projects.
Donors will be followed from their selection until 6 months after their last valid stool donation.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 17 kg/m² \< body mass index \< 30 kg/m²
* Regular bowel movement defined as at least 1 stool every other day and maximum 2 stools per day
* Subject with health insurance (AME excepted)
* Informed written consent
1. Infectious risk :
\- Known HIV, HBV, HCV, HTLV infection
\- Residence of more than 2 years in the intertropics zone within the previous 5 years
\- Hospitalization abroad for more than 24 hours in the last 12 months (including a member of the healthy volunteers donor's entourage)
\- Risk factors for Creutzfeldt-Jakob disease (history: treatment with extractive growth hormone, a family case of transmissible spongiform subacute encephalopathy, surgery with opening of the dura or neurosurgery or invasive brain exploration before 1 January 1995, stay in United Kingdom for a duration greater than 1 year cumulatively between 1980 and 1996 or the presence of neurological or neuropsychiatric scalable recent clinical signs)
* Previous history of typhoid fever, tuberculosis and malaria
* Past or current injection drug user or regular use of other drug
2. Gastrointestinal disease:
\- Personal or 1st degree family history of: inflammatory bowel disease or celiac disease
\- Personal history of irritable bowel syndrome, idiopathic chronic constipation or chronic diarrhea
\- Previous history of gastrointestinal neoplasia or polyps
\- Family history of 1st degree gastrointestinal neoplasia or polyps before age 60
3. 1st degree family history of one of the following autoimmune or inflammatory disease : inflammatory arthritis, psoriasis, multiple sclerosis, type I diabetes, spondylitis, lupus and Basedow disease
\- If family history unknown in the first degree, the donor is not eligible
4. Previous history of :
* Subject prone to hemorrhoids (at least 1 event within the previous 1 year)
* Subject with an active chronic illness (except active chronic mild allergic disease o (example: allergic rhinitis, chronic eczema…))
* Diagnosis of Gilbert's syndrome done by screening is not a chronic disease. The healthy volunteer donor will therefore remain eligible.
* Serious allergy requiring hospitalization within the previous 12 months
* Curative long-term treatment
* Severe allergy requiring hospitalization in the last 12 months
* Allogeneic human or animal tissue or organ transplant
* 5- Factors that may affect the composition of the intestinal microbiota:
* Special Diet (example: gluten-free...)
* Lactose-free, vegetarian and vegan diets are permitted.
* Pregnancy or breastfeeding
* Taking immunosuppressants (eg calcineurin inhibitors, corticosteroids, biological agents, etc.)
* Antineoplastic chemotherapy
1. Infectious risk :
* Unprotected sexual intercourse with a new partner in the previous 4 months and/or sexual intercourse with several different persons within the previous 4 months
* sexual partner who has had more than 1 partner within the previous 4 months and/or
* sexual transmitted infection within the previous 4 months (healthy volunteer donor himself or sexual partner)
* Sexual relationship in exchange for money or drugs in the last 12 months. (healthy volunteer donor himself or sexual partner)
* Sexual relationship with a partner with positive serology for HIV, viral hepatitis B or C, in the last 6 months.
* Sexual relationship with a partner who has used intravenous drugs, doping substances
* Hospitalization abroad for more than 24 hours in the last 12 months (healthy volunteer or entourage)
* Travelling within the previous 3 months except : Germany, Austria, Belgium, Spain, Finland, Ireland, Italia, Luxembourg, Netherland, Portugal, Greece, Slovenia, Cyprus, Malta, Slovakia, Estonia , Bulgaria, Croatia , Hungary, Latvia , Lithuania, Poland , Romania, Czech Republic, the United Kingdom, Denmark, Norway, Sweden, Switzerland, USA or Canada.
* Blood transfusion, piercing (including earrings) or tattoo within the previous 4 months
* Surgery (all types) or hospitalization within the previous 4 months
* Person living under the same roof with an infectious or contagious disease (i.e who have been hospitalized) within the previous 4 months
* Blood exposure accident (for wound, pricking or projection ...) within the previous 4 months
* Dental care within the previous 7 days
* Gastroenteritis within the previous 3 months (defined by acute onset of diarrhea (\> 3 soft or liquid stools per day) and duration \< one week)
* Episode of infection or skin infection/lesion within the previous 15 days 2-Risk linked to Covid-19
* Confirmed infection in the previous 28 days (after symptoms have ceased)
* Clinical signs of suspected infection (chill, cough, fever, dyspnea, myalgia, asthenia, malaise, pharyngeal pain, anosmia , ageusia, rhinorrhea, chest pain, headache, diarrhea) in the previous 28 days (after the end of symptoms)
* Having been in risky contact (according to the definition of Santé Publique France with a person whose infection is confirmed or suspected: "14 days after the last risky contact: if the recommended screening tests in the event of risky contact between D15-D28 are negative "In the 28 days preceding inclusion in the absence of a screening test. Healthcare professionals using recommended protective measures with COVID patients are not considered high-risk contacts 3- Monkeypox risk
* Confirmed or suspected infection within the previous 42 days ( after beginning of symptoms)
* Risky contact with a person with confirmed or suspected infection within the previous 21 days (from the date of last contact)
* Person who received the vaccine Imvanex within the previous 28 days ( after the last injection).
4- vaccination in the previous 15 days
5- Factors that may affect the composition of the intestinal microbiota:
* Taking antibiotic or antifungal (oral) in the previous 3 months before donation
* Taking non-steroidal anti-inflammatory drugs (oral) in the previous month before donation
* Taking corticosteroids (oral) in the previous 4 weeks before donation. Corticosteroids allowed if taken more than 4 weeks before donation. and not for an autoimmune or inflammatory disease.
18 Years
49 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CRB-SAT BARM APHP.SU
UNKNOWN
CRSA UMRS 938
UNKNOWN
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mélissa Montil
Role: PRINCIPAL_INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
LRIPH CRC-Est SAT
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Melissa MONTIL
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-A01401-42
Identifier Type: OTHER
Identifier Source: secondary_id
APHP220606
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.